
    
      A phase II randomized study of the combination of Ribociclib plus goserelin acetate with
      Hormonal Therapy versus physician choice hemotherapy in premenopausal or perimenopausal
      patients with hormone receptorpositive/ HER2-negative inoperable locally advanced or
      metastatic breast cancer - RIGHT Choice Study
    
  